NCT07130864 Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp.
| NCT ID | NCT07130864 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Khyber Teaching Hospital |
| Condition | Laparoscopic Cholecystectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 136 participants |
| Start Date | 2025-05-23 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 136 participants in total. It began in 2025-05-23 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is controversy about timing of cholecystectomy after the common bile duct is cleared of stones. our study aims to compare the results of early vs late cholecystectomy.
Eligibility Criteria
Inclusion criteria : .All patients undergoing laparoscopic cholecystectomy who had concomitant choledocholithiasis for which ercp is done. exclusion criteria: .Non consenting indviduals
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07130864 clinical trial?
This trial is open to participants of all sexes, studying Laparoscopic Cholecystectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07130864 currently recruiting?
Yes, NCT07130864 is actively recruiting participants. Contact the research team at saeedkmc2020@gmail.com for enrollment information.
Where is the NCT07130864 trial being conducted?
This trial is being conducted at Peshawar, Pakistan.
Who is sponsoring the NCT07130864 clinical trial?
NCT07130864 is sponsored by Khyber Teaching Hospital. The trial plans to enroll 136 participants.